This investigation aims to describe the treatment patterns and corresponding outcomes of women diagnosed with metastatic or recurrent BC in Alberta, Canada, between 2010 and 2019, stratified by HER2 status (IHC0/-low). This evidence concerns the gene ERBB2 and breast cancer.